Rhythm Pharmaceuticals First Patients Dosed In Phase 2 Trial Evaluating Oral MC4R Agonist LB54640 In Hypothalamic Obesity

7/23/24 8:14:47 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $RYTM alert in real time by email

-- LB54640 has shown targeted effect on MC4R without hyperpigmentation --

BOSTON, July 23, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that the first patients have been dosed in the Company's Phase 2 clinical trial evaluating LB54640, an investigational oral melanocortin-4 receptor (MC4R) agonist, in hypothalamic obesity.

Get the next $RYTM alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$RYTM

Date	Price Target	Rating	Analyst
10/21/2024	$70.00	Buy	Guggenheim
9/18/2024	$64.00	Buy	H.C. Wainwright
9/17/2024	$64.00	Mkt Outperform	JMP Securities
5/8/2024	$49.00 → $42.00	Buy → Neutral	BofA Securities
12/19/2023	$29.00 → $55.00	Equal-Weight → Overweight	Morgan Stanley
8/1/2023	$22.00 → $27.00	Neutral → Buy	BofA Securities
1/18/2023	$52.00	Buy	Canaccord Genuity
8/8/2022	$28.00	Neutral → Buy	Goldman

More analyst ratings

Rhythm Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Update
-- Third quarter 2024 net revenue from global sales of IMCIVREE® (setmelanotide) of $33.3 million -- -- Adult patients with acquired hypothalamic obesity (N=8) achieved mean BMI reduction of 12.8% on setmelanotide therapy at three months in French early-access program -- -- Top-line data readout for Phase 3 trial evaluating setmelanotide in 120 patients with acquired hypothalamic obesity on track for 1H 2025 -- -- sNDA to expand IMCIVREE label to include patients as young as 2 years old in approved indications accepted by FDA for Priority Review with PDUFA goal date of Dec. 26, 2024 -- -- Cash on-hand expected to support planned operations into 2026 -- -- Management to host conferenc
11/5/24 4:01:00 PM ET
$RYTM
Biotechnology: Pharmaceutical Preparations
Health Care
Rhythm Pharmaceuticals Announces Five New Data Presentations at ObesityWeek® 2024
-- Real-world data showed mean BMI decrease of 12.8% in adult patients with acquired hypothalamic obesity (N=8) at three months on setmelanotide therapy; mean BMI decrease of 21.3% in patients (n=5) who reached six months -- -- Greater reduction in fat mass (29.7%) versus reduction in lean muscle mass (7.7%) reported from Phase 2 trial extension in patients with acquired hypothalamic obesity (n=11) after 12 months -- -- Positive data from Phase 2 DAYBREAK stage 2 showed mean BMI reduction of 12.4% in patients with rare MC4R pathway diseases on continuous setmelanotide therapy for 40 weeks (n=32) -- -- New Phase 3 VENTURE trial data showed mean BMI reduction of 23.8% in pediatric patient
11/4/24 4:01:00 PM ET
$RYTM
Biotechnology: Pharmaceutical Preparations
Health Care
Rhythm Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 5, 2024
-- Five posters to be presented at ObesityWeek® -- BOSTON, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 5:00 p.m. ET on Tuesday, November 5, 2024 to report its third quarter 2024 financial results and provide a corporate update. The conference call will be hosted live from The Obesity Society's Annual Meeting, ObesityWeek® in San Antonio, TX. To access the live conference call, participants may register here. While not required, it is recommended that pa
10/23/24 8:00:00 AM ET
$RYTM
Biotechnology: Pharmaceutical Preparations
Health Care

Rhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, including New Real-world Data in Pediatric Patients with Acquired or Congenital Hypothalamic Obesity Treated with Setmelanotide
-- Four Pediatric patients treated in French early-access program achieved meaningful weight reduction at three months on setmelanotide therapy -- -- Rhythm announced plans for a new substudy to evaluate setmelanotide therapy in patients with congenital hypothalamic obesity -- BOSTON, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the presentation of new, real-world data that showed four pediatric patients with acquired hypothalamic obesity or congenital hypothalamic obesity achieved >5% weight reduction at t
11/18/24 7:00:00 AM ET
$RYTM
Biotechnology: Pharmaceutical Preparations
Health Care
Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Study of Setmelanotide in Patients Between 2 and 5 Years Old in The Lancet Diabetes & Endocrinology
BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the publication of results from its Phase 3 VENTURE trial evaluating setmelanotide, a melanocortin-4 receptor (MC4R) agonist, in children between the ages of 2 and younger than 5 years old with Bardet Biedl syndrome (BBS) or pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency. The data are published in the peer-reviewed journal The Lancet Diabetes & Endocrinology. "Severe, early-onse
11/13/24 6:30:00 PM ET
$RYTM
Biotechnology: Pharmaceutical Preparations
Health Care
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that on November 7, 2024, the Compensation & Management Development Committee of Rhythm's Board of Directors granted inducement restricted stock units, or RSUs, covering an aggregate of 15,750 shares of its common stock to three new employees. These inducement RSUs are subject to the terms of the Rhythm Pharmaceuticals, Inc. 2022 Employment Inducement Plan (the "Inducement Plan"). The Inducement Plan is used exclusively for the grant of equity awards to in
11/13/24 4:01:00 PM ET
$RYTM
Biotechnology: Pharmaceutical Preparations
Health Care

Rhythm Pharmaceuticals Announces Appointment of Alastair Garfield, Ph.D., as Chief Scientific Officer
BOSTON, July 08, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced the appointment of Alastair "Al" Garfield, Ph.D. as Chief Scientific Officer, effective July 1. "We are excited to welcome Al back to Rhythm as we continue to leverage our understanding of the melanocortin-4 receptor (MC4R) pathway to bring potential therapies to patients and their families," said David Meeker, M.D., Rhythm Chairman, Chief Executive Officer and President. "Al's leadership and established scientific expertise and experience
7/8/24 8:00:00 AM ET
$RYTM
Biotechnology: Pharmaceutical Preparations
Health Care
Rhythm Pharmaceuticals Appoints Dana Washburn, M.D., as Senior Vice President of Clinical Development
BOSTON, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced the appointment of Dana Washburn, M.D., as Senior Vice President of Clinical Development and as a member of the Company's Executive Leadership Team, effective September 26, 2022. As SVP of Clinical Development, Dr. Washburn will lead the Company's robust clinical development program, clinical operations, and data management. "Dr. Washburn is a collaborative, resourceful leade
10/6/22 4:02:00 PM ET
$RYTM
Biotechnology: Pharmaceutical Preparations
Health Care
Wren Appoints Bart Henderson as Chief Executive Officer
Wren Therapeutics, a biopharmaceutical company transforming drug discovery for neurodegenerative diseases, today announced the appointment of Bart Henderson as Chief Executive Officer. Wren's unique drug discovery platform harnesses advances in the biophysics of protein assembly dynamics to target the toxic fleeting protein intermediates, the oligomers, in neurodegenerative disease pathways, and discover small molecules that can block their generation with precision. Bart brings broad leadership experience in the biotechnology industry as a founder and co-founder of several companies including Torque (now Repertoire Immune Medicines), Rhythm (NASDAQ:RYTM) and its subsidiary Motus (acquired
3/4/22 8:00:00 AM ET
$RYTM
Biotechnology: Pharmaceutical Preparations
Health Care

Rhythm Pharmaceuticals First Patients Dosed In Phase 2 Trial Evaluating Oral MC4R Agonist LB54640 In Hypothalamic Obesity

Chat with this insight

Recent Analyst Ratings for $RYTM

$RYTM Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

EVP, Head of North America Lee Jennifer Kayden exercised 60,981 shares at a strike of $19.59 and sold $4,434,882 worth of shares (66,861 units at $66.33), decreasing direct ownership by 86% to 972 units (SEC Form 4)

Chief Technical Officer Shulman Joseph sold $882,341 worth of shares (13,281 units at $66.44) and exercised 13,281 shares at a strike of $12.63 (SEC Form 4)

Amendment: Chief Technical Officer Shulman Joseph exercised 69,160 shares at a strike of $20.54, increasing direct ownership by 1,320% to 74,430 units (SEC Form 4)

$RYTM Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Rhythm Pharmaceuticals Inc.

Amendment: SEC Form SC 13G/A filed by Rhythm Pharmaceuticals Inc.

Amendment: SEC Form SC 13G/A filed by Rhythm Pharmaceuticals Inc.

$RYTM SEC Filings

SEC Form 10-Q filed by Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

Rhythm Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

$RYTM Market Insights

Live Market Insights

A Glimpse Into The Expert Outlook On Rhythm Pharmaceuticals Through 4 Analysts

Needham Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $55

Rhythm Pharmaceuticals First Patients Dosed In Phase 2 Trial Evaluating Oral MC4R Agonist LB54640 In Hypothalamic Obesity

$RYTM Financials

Live finance-specific insights

$RYTM Press Releases

Fastest customizable press release news feed in the world

$RYTM Leadership Updates

Live Leadership Updates

$RYTM Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Rhythm Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Update

Rhythm Pharmaceuticals Announces Five New Data Presentations at ObesityWeek® 2024

Rhythm Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 5, 2024

Rhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, including New Real-world Data in Pediatric Patients with Acquired or Congenital Hypothalamic Obesity Treated with Setmelanotide

Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Study of Setmelanotide in Patients Between 2 and 5 Years Old in The Lancet Diabetes & Endocrinology

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

Rhythm Pharmaceuticals Announces Appointment of Alastair Garfield, Ph.D., as Chief Scientific Officer

Rhythm Pharmaceuticals Appoints Dana Washburn, M.D., as Senior Vice President of Clinical Development

Wren Appoints Bart Henderson as Chief Executive Officer

Guggenheim initiated coverage on Rhythm Pharmaceuticals with a new price target

H.C. Wainwright initiated coverage on Rhythm Pharmaceuticals with a new price target

JMP Securities initiated coverage on Rhythm Pharmaceuticals with a new price target

Recent Analyst Ratings for
$RYTM

$RYTM
Insider Trading

$RYTM
Large Ownership Changes

$RYTM
SEC Filings

$RYTM
Market Insights

$RYTM
Financials

$RYTM
Press Releases

$RYTM
Leadership Updates

$RYTM
Analyst Ratings